Skip to content
OpenCapital
Get started

Anika Therapeutics ANIK Q1 2026 earnings

Reported April 29, 2026 · Before market open

Revenue$29.6MBeat by $1.5M
EPS$0.27Beat by $0.34
Revenue estimate$28.1M
EPS estimate-$0.07

Next report

Jul 29, 2026 (Today)
Revenue estimate$29.2M
EPS estimate$0.03
View report

Financials

Q1 2026

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$199.85M+23.0%
P/S1.7×-0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%—

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Segments

By geography

See full
Europe$6.7M+15.0%
Other Location$4.4M+10.2%

By product

See full
OEM Channel$17.0M+14.3%
Commercial Channel$12.6M+11.7%

Versus estimates

Revenue

Q1 2026$29.6MBeat by $1.5M
Q4 2025$30.6MBeat by $1.7MQ3 2025$27.8MBeat by $17.0KQ2 2025$28.2MBeat by $685.7KQ1 2025$26.2MMiss by $1.9MQ4 2024-$1.3MMiss by $29.4M

Diluted EPS

Q1 2026$0.27Beat by $0.34
Q4 2025$0.31Beat by $0.44Q3 2025$0.04Beat by $0.02Q2 2025-$0.13In lineQ1 2025-$0.06Miss by $0.15Q4 2024-$0.03Miss by $0.02

Ask the moment Anika Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Anika Therapeutics report Q1 2026 earnings?
Anika Therapeutics (ANIK) reported Q1 2026 earnings on April 29, 2026 before market open.
What were Anika Therapeutics's Q1 2026 revenue and EPS?
Anika Therapeutics reported revenue of $29.6M and eps of $0.27 for Q1 2026.
Did Anika Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $28.1M by $1.5M. EPS beat the consensus estimate of $-0.07 by $0.34.
How did Anika Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.2% from $26.2M a year earlier.
Where can I find Anika Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-002799) and the 10-Q periodic report (0001171843-26-002852) directly on SEC EDGAR. The filing index links above go to sec.gov.